Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/30644| Title: | Active surveillance versus enzalutamide for low-risk prostate cancer- was it really a trial we needed? | Austin Authors: | Williams, Isabella Sc;Perera, Sachin;Murphy, Declan G;Corcoran, Niall M;Bolton, Damien M ;Lawrentschuk, Nathan | Affiliation: | Department of Urology and Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Australia.. EJ Whitten Prostate Cancer Research Centre at Epworth, Melbourne, Australia.. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.. Urology Surgery (University of Melbourne) |
Issue Date: | 25-Jul-2022 | Date: | 2022 | Publication information: | BJU International 2022; 130(5): 580-581 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/30644 | DOI: | 10.1111/bju.15860 | ORCID: | 0000-0002-4149-468X 0000-0002-7500-5899 0000-0001-8553-5618 0000-0002-5145-6783 |
Journal: | BJU international | PubMed URL: | 35879832 | PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/35879832/ | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.